Tapentadol tablets

Tapentadol Tablets

Form: Oral Tablets

Strength: 50 mg, 100 mg, 150 mg, 200 mg

Reference Brands: Nucynta(US); Palexia (EU)

Category: Analgesic

Tapentadol tablets are approved in the US and EU for moderate to severe pain management. In the US, brands like Nucynta are regulated by the FDA, supported by extensive clinical data, with strict controls due to dependence potential. In the EU, approval by the EMA requires comprehensive dossiers demonstrating safety, efficacy, and manufacturing standards. Both regions enforce strict regulations, including labeling, pharmacovigilance, and post-market surveillance. For regulatory dossier preparation, compliance, and registration support, visit PharmaTradz. We facilitate seamless market access for tapentadol tablets while ensuring adherence to European and American standards for safe, effective use of opioids in pain management.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Dexketoprofen + Tramadol Tablets

Strength: 25 mg dexketoprofen + 37.5 mg tramadol

Form: Tablets

Reference Brands: Enantyum(EU)

View Details Get Enquiry
Paracetamol + Codeine Tablets

Strength: 300 mg paracetamol + 30 mg codeine; 300 mg + 60 mg

Form: Tablets

Reference Brands: Tylenol with Codeine(US)

View Details Get Enquiry
Aceclofenac + Paracetamol Tablets

Strength: 100 mg Aceclofenac + 325 mg Paracetamol

Form: Tablets

Reference Brands: Generic formulations marketed under different names

View Details Get Enquiry
Tramadol + Paracetamol Tablets

Strength: 37.5 mg tramadol + 325 mg paracetamol; 75 mg + 650 mg

Form: Oral Tablets

Reference Brands: Ultracet(US); Tramacet(EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

We use cookies to ensure you get the best experience. Learn more